A recent analysis from the Grattan Institute highlights that the pharmacy sector’s powerful lobby is prioritizing its interests over those of taxpayers. According to the report, the Pharmacy Guild of Australia, which represents the majority of pharmacy owners, is significantly influencing policy in a manner that ultimately disadvantages patients by restricting access to lower-cost medications.
The Grattan Institute, a public policy research organization, asserts that the current funding structure for pharmacies requires significant reform. Lobbying efforts by the Pharmacy Guild have resulted in substantial profits for its members, while the negotiation process surrounding nearly $4 billion in taxpayer funding occurs without public oversight or transparency regarding the criteria used for these decisions.
Peter Breadon, the health director at Grattan and the report’s lead author, commented on the situation, stating, “This illustrates an improper level of influence from a self-serving entity.” He pointed out that no other major health funding model in Australia operates under such conditions, making it challenging to find similar practices in other countries.
The report criticizes the “Community Pharmacy Agreements,” which it characterizes as excessively favorable to pharmacy owners and protective against declines in revenue. Breadon noted that a survey conducted by the Guild indicated that member profits have more than doubled over the past ten years. Conversely, Simon Blacker, the Guild’s vice president, defended the funding agreements as reflective of the vital role pharmacies play, including services like vaccination and chronic disease management.
Blacker also highlighted the Guild’s efforts to push for lower costs under the Pharmaceutical Benefits Scheme (PBS), asserting that their advocacy led to the first-ever reduction in out-of-pocket expenses for medicines within the PBS framework.
The report also critiques various fees that community pharmacies charge, including a “dispensing fee” of approximately $9, which is intended to cover the costs associated with processing prescriptions and advising patients. However, the Grattan analysis found that these fees are not necessarily aligned with actual dispensing costs, and efforts to clarify these costs have been obstructed by the Guild, leading to negotiations that lack transparency.
Furthermore, the report raises concerns about an “allowable additional patient charge,” enabling pharmacies to impose an extra fee of $2.80 on certain medications. The Grattan Institute argues that this fee does not equate to the value of services provided and should be eliminated. Additionally, pharmacies face discouragement from offering discounts on medications, with a longstanding $1 discount set to be phased out by 2029. Although this discount may seem minimal, it saved patients approximately $48 million in the fiscal year 2022-23.
The report also discusses regulatory restrictions that limit where new pharmacies can be established, typically requiring a minimum distance of 10 kilometers from existing pharmacies, although exceptions exist. The Guild defends these regulations, claiming they prevent pharmacies from concentrating solely in lucrative areas, thereby ensuring access for vulnerable populations. However, the Grattan Institute argues that these limitations protect existing pharmacies from competition and should be removed to foster a more competitive market, which could lead to increased pharmacy numbers, extended hours, and potentially lower prices.
To enhance pharmacy access in rural regions, Breadon advocates for government intervention through workforce incentives and subsidies. He emphasizes that targeted support can broaden access to medications while maintaining competitive dynamics across the sector.
The Grattan Institute recommends the abolition of Community Pharmacy Agreements by 2029 when the current contracts lapse. Should the government opt against this course of action, the report suggests involving pharmacists and patients in future negotiations and entrusting the Independent Health and Aged Care Pricing Authority with the task of determining funding rates.
Health Minister Mark Butler has refrained from commenting on whether the government will adopt the report’s proposals, noting that the existing pharmacy agreement has included consultations with relevant stakeholders.
